News | July 08, 2022
WuXi STA opens Oligonucleotide and Peptide manufacturing facility
Site Enhances New Modality CRDMO Platform Capacity for Customers
Site Enhances New Modality CRDMO Platform Capacity for Customers
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
The capacity addition in Suwa is part of Saint-Gobain Life Sciences ongoing investment plan to globally expand production capacity for its products and services used throughout the bioprocessing industry
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
The inspection was a Pre-Approval cum cGMP inspection and it covered 15 ANDAs
The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland
Subscribe To Our Newsletter & Stay Updated
